“Monoclonal antibody therapy of T cell lymphoma: single agent trials of anti-CD2 (Siplizumab) and anti-CD4 (Humax-CD4)”, Hematol Meeting Rep, vol. 3, no. 1, Jun. 2009, doi: 10.4081/hmr.v3i1.532.